PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 6, 2026Cancers0 citationsOpen Access

Protein Nanocarriers: Targeted Theranostics for Cancer Treatment and Imaging

View Full Paper
RCReyhan Dilsu ColpanNTNeil R. ThomasLTLyudmila Turyanska

Key Points

  • This review aims to explore the advancements in protein-based nanocarriers for targeted cancer treatment and imaging applications.
  • Summarized recent advances in targeted protein-based nanocarriers.
  • Discussed specific types like albumin and ferritin.
  • Emphasized receptor-specific targeting mechanisms.
  • Integrated various imaging modalities and their advantages.
  • Highlighted the importance of advanced preclinical models.
  • Identified unique physicochemical and biological properties of protein nanocarriers.
  • Showed the potential for improved targeted cancer therapy and diagnostics.
  • Discussed advantages and limitations of different imaging techniques.
  • Provided insights into significant studies influencing future protein nanocarrier development.

Abstract

Protein-based nanocarriers have gained considerable attention for targeted cancer theranostic applications due to their inherent biocompatibility, biodegradability, and facile functionalisation. In addition, some of their properties, such as self-assembling nature, low immunogenicity (if species matched), molecular recognition ability, and lack of persistence due to degradation into proteinogenic amino acids, make them highly suitable for oncology-related applications. Each protein-based nanocarrier exhibits unique physicochemical and biological properties. In this review, we summarise recent advances in targeted protein-based nanocarriers, including albumin, lipoproteins, ferritin, viral protein capsids, fibrin type proteins and silk proteins, emphasising receptor-specific targeting mechanisms, the integration of various imaging modalities along with their advantages and limitations, and the importance of employing advanced preclinical models for translational theranostic applications. This review also discusses the most recent and significant studies in the field, providing useful insights into future directions of protein-based nanocarriers for cancer theranostics.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Colpan et al. (2026) studied this question.

synapsesocial.com/papers/69aa70a9531e4c4a9ff5aa60https://doi.org/10.3390/cancers18050832
Ask AI
Helpful
Bookmark
Share
View Full Paper